```html

Juvenile Systemic Lupus Erythematosus (JSLE)

Overview

Systemic lupus erythematosus (SLE) is an autoimmune disease in which the body’s immune system attacks its own tissues. When SLE begins before the age of 18, it is referred to as juvenile systemic lupus erythematosus (JSLE) or childhood‑onset lupus.

• Who it affects: Girls are far more likely to develop JSLE than boys (approximately 4–5 : 1). It can occur in any ethnic group, but the highest prevalence is seen in African‑American, Hispanic, Asian, and Native American children.
• Prevalence: The incidence of JSLE in the United States is about 2–4 cases per 100,000 children per year, with a cumulative prevalence of roughly 30–50 per 100,000 children. Worldwide estimates vary, but many registries report prevalence rates 2–3 times higher in non‑White populations (source: CDC, Mayo Clinic).

JSLE is a chronic, potentially life‑threatening condition, yet with modern therapy many patients achieve remission and lead active lives.

Symptoms

JSLE can involve virtually any organ system. The most common presenting features in children are:

General / Constitutional

• Fatigue – persistent tiredness that does not improve with rest.
• Fever – low‑grade fevers often without an obvious infection.
• Weight loss – unintended loss of weight over weeks to months.

Skin

• Butterfly (malar) rash – a red, flat or raised rash over the cheeks and bridge of the nose, worsened by sunlight.
• Discoid rash – round, scaly patches that can scar.
• Photosensitivity – skin eruptions develop or intensify after sun exposure.
• Subacute cutaneous lupus – annular or papular lesions that often appear on the trunk or arms.
• Oral or nasal ulcers – painless sores inside the mouth or on the nasal mucosa.

Musculoskeletal

• Arthritis – non‑erosive joint pain, swelling, and stiffness, most often affecting the hands, wrists, and knees.
• Myo­mytitis – muscle inflammation causing weakness, especially in the proximal muscles.

Renal (Kidney)

• Lupus nephritis – proteinuria, hematuria, hypertension, or impaired kidney function. Around 50‑60 % of children develop renal involvement within the first 2 years of disease.

Hematologic

• Autoimmune hemolytic anemia – destruction of red blood cells.
• Leukopenia – low white‑blood‑cell count.
• Thrombocytopenia – low platelet count, leading to easy bruising or bleeding.

Neurologic / Psychiatric

• Headaches and cognitive dysfunction (“brain fog”).
• Seizures or psychosis – less common but serious.
• Peripheral neuropathy – tingling or burning sensations.

Cardiopulmonary

• Pleural effusion or pericarditis – chest pain that worsens with deep breaths.
• Pulmonary hypertension – shortness of breath, fatigue, and exercise intolerance.

Other

• Raynaud’s phenomenon – fingers or toes turn white/blue in cold.
• Hair loss (alopecia) – patchy or diffuse thinning.

Because symptoms may wax and wane, a child may present with only one organ’s involvement initially, making early recognition challenging.

Causes and Risk Factors

Underlying Mechanism

JSLE arises from a complex interplay of genetic susceptibility, hormonal influences, and environmental triggers that cause the immune system to produce auto‑antibodies (most notably anti‑double‑stranded DNA and anti‑Smith antibodies). These auto‑antibodies form immune complexes that deposit in tissues, provoking inflammation and organ damage.

Genetic Factors

• Family history of SLE or other autoimmune diseases increases risk (odds ratio ≈ 3–4).
• Specific genes such as HLA‑DR2, HLA‑DR3, and variants in CTLA4, IRF5, and PTPN22 have been linked to JSLE.

Hormonal Influence

Female predominance suggests estrogen may amplify immune responses. Puberty often heralds disease onset, especially in girls.

Environmental Triggers

• Ultraviolet (UV) light – sun exposure can precipitate skin lesions and systemic flares.
• Infections – Epstein‑Barr virus, cytomegalovirus, and recent bacterial infections have been associated with disease onset.
• Medications – certain drugs (e.g., procainamide, hydralazine) can induce a lupus‑like syndrome, though true JSLE is rarely drug‑induced.

Other Risk Factors

• Ethnicity: African‑American, Hispanic, Asian, and Native American children have higher incidence.
• Living in areas with high UV index.
• Early exposure to tobacco smoke (including secondhand).

Diagnosis

Diagnosing JSLE requires a combination of clinical assessment and laboratory testing. The 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria are most widely used, assigning weighted points for clinical and immunologic findings. A total score ≥ 10 confirms SLE.

Clinical Evaluation

• Detailed medical history (symptom chronology, family history, photosensitivity).
• Comprehensive physical exam focusing on skin, joints, kidneys, heart, lungs, and neurologic status.

Laboratory Tests

• Antinuclear antibody (ANA) – positive in > 95 % of patients; used as a screening test.
• Anti‑double‑stranded DNA (anti‑dsDNA) & anti‑Smith (anti‑Sm) – highly specific for SLE, correlate with disease activity, especially renal disease.
• Complement levels (C3, C4) – often low during active disease.
• Complete blood count (CBC) – assesses anemia, leukopenia, thrombocytopenia.
• Urinalysis & urine protein/creatinine ratio – screens for lupus nephritis.
• Serum creatinine, eGFR – kidney function.
• Anti‑phospholipid antibodies – identify risk for clotting.

Imaging & Specialty Tests

• Renal biopsy – gold standard for classifying lupus nephritis (WHO/ISN/RPS classification).
• Echocardiogram – evaluates pericardial effusion or valvular disease.
• Chest X‑ray or CT – assesses pleuritis, pulmonary infiltrates.
• Brain MRI – indicated for neurologic symptoms.

Because children may have overlapping features with other rheumatic diseases (e.g., juvenile idiopathic arthritis, vasculitis), a pediatric rheumatologist should confirm the diagnosis.

Treatment Options

Treatment goals are to control inflammation, prevent organ damage, minimize medication side effects, and maintain quality of life. Management is individualized based on organ involvement and disease severity.

First‑Line (Mild‑to‑Moderate) Therapy

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – for arthritis and serositis (e.g., ibuprofen, naproxen).
• Antimalarial drug hydroxychloroquine (HCQ) – cornerstone of long‑term therapy; reduces flares and improves survival. Dose ≤ 5 mg/kg/day to avoid retinal toxicity (baseline and annual ophthalmology exams required).
• Low‑dose oral corticosteroids – prednisone ≤ 0.5 mg/kg/day for acute control, tapered quickly if possible.

Moderate‑to‑Severe Disease / Organ‑Threatening Involvement

• High‑dose corticosteroids – IV methylprednisolone pulses (e.g., 30 mg/kg up to 1 g daily for 3 days) for rapid control of nephritis, CNS involvement, or severe serositis.
• Immunosuppressive agents:
  • Mycophenolate mofetil (MMF) – first‑line for proliferative lupus nephritis (class III/IV); dosing 600 mg/m² twice daily.
  • Cyclophosphamide – intravenous monthly pulses for severe nephritis or CNS disease; fertility‑preserving measures (e.g., GnRH analogs) recommended for adolescents.
  • Azathioprine – maintenance therapy after induction.
  • Methotrexate – useful for arthritis and skin disease.
• Biologic agents:
  • Belimumab – anti‑BLyS monoclonal antibody; approved for patients ≥ 5 years with active disease despite standard therapy.
  • Rituximab – anti‑CD20; used off‑label for refractory nephritis or neuro‑lupus.

Adjunctive Therapies

• Vitamin D supplementation (800–1000 IU/day) to counter steroid‑induced bone loss.
• Calcium (1,000–1,300 mg/day) and bone‑protective agents (e.g., bisphosphonates) if long‑term steroids are required.
• Antihypertensive agents (ACE inhibitors or ARBs) for renal protection.
• Anticoagulation (low‑dose aspirin or warfarin) in patients with persistent antiphospholipid antibodies.

Lifestyle & Supportive Measures

• Sun protection – broad‑spectrum sunscreen SPF 30+, protective clothing, and avoidance of peak UV hours.
• Balanced diet rich in fruits, vegetables, lean protein, and omega‑3 fatty acids.
• Regular physical activity (age‑appropriate exercise) to maintain joint flexibility and cardiovascular health.
• Psychosocial support – counseling, peer groups, and school accommodations.

Living with Juvenile Systemic Lupus Erythematosus

Daily Management Tips

• Medication schedule – use a pill organizer or smartphone reminders; keep a written medication list for school staff and emergency personnel.
• Sun safety routine – apply sunscreen 15 minutes before going outside, reapply every 2 hours, and wear wide‑brim hats.
• Regular monitoring – attend rheumatology appointments every 3‑6 months, and labs (CBC, CMP, complement, urine protein) as directed.
• School planning – provide a 504/IEP plan outlining medication administration, need for rest periods, and accommodations for cognitive “brain fog.”
• Vaccinations – stay up‑to‑date with non‑live vaccines (influenza, HPV, COVID‑19). Discuss timing of live vaccines with the rheumatologist, especially if on high‑dose steroids.
• Emotional wellbeing – chronic illness can affect mood; consider therapy, support groups, or counseling.
• Family education – involve parents and siblings in learning about flare signs and medication side effects.

Monitoring for Disease Activity

Keep a simple diary noting:

1. New or worsening joint pain/swelling.
2. Skin rash changes.
3. Fever, night sweats, or unexplained weight loss.
4. Urine changes (color, foaming) or swelling of ankles.
5. Neurologic symptoms (headache, confusion, seizures).

Report any of these promptly to the rheumatology team.

Prevention

Because JSLE is largely driven by genetics, true primary prevention is not possible. However, steps can reduce disease flares and secondary complications:

• Sun protection – as detailed above.
• Avoid tobacco exposure – both active smoking and second‑hand smoke worsen disease activity.
• Prompt infection control – hand hygiene, vaccinations, and early treatment of infections reduce immune activation.
• Stress management – chronic stress can trigger flares; encourage relaxation techniques (deep breathing, yoga, mindfulness).
• Medication adherence – missing doses of hydroxychloroquine is linked to higher flare rates.

Complications

If not adequately controlled, JSLE can lead to serious, sometimes irreversible damage:

• Renal failure – leading to chronic kidney disease or need for dialysis/transplant.
• Neuropsychiatric lupus – seizures, psychosis, stroke, or cognitive decline.
• Cardiovascular disease – premature atherosclerosis, myocardial infarction, or pericarditis.
• Osteoporosis – from chronic steroids and inflammation.
• Infections – immunosuppressive therapy heightens risk for bacterial, viral, and fungal infections.
• Pregnancy complications – later in life, women with a history of JSLE have higher rates of preeclampsia, preterm birth, and fetal loss.
• Growth retardation – chronic disease and steroids can impair height gain.
• Psychosocial impact – depression, anxiety, and reduced school performance.

When to Seek Emergency Care

References

• Mayo Clinic. Lupus in Children. Accessed May 2026.
• Centers for Disease Control and Prevention. Lupus in Children. 2023.
• American College of Rheumatology. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020.
• National Institutes of Health. Lupus Nephritis. Updated 2022.
• Cleveland Clinic. Systemic Lupus Erythematosus (SLE). 2024.
• World Health Organization. Lupus and Autoimmune Diseases. 2022.

```